...
首页> 外文期刊>Acta biochimica Polonica >Plasma levels of VEGF-A, VEGF B, and VEGFR-1 and applicability of these parameters as tumor markers in diagnosis of breast cancer
【24h】

Plasma levels of VEGF-A, VEGF B, and VEGFR-1 and applicability of these parameters as tumor markers in diagnosis of breast cancer

机译:血浆VEGF-A,VEGF B和VEGFR-1的水平以及这些参数作为肿瘤标志物在乳腺癌诊断中的适用性

获取原文
           

摘要

The VEGF family members are important factors in promoting angiogenesis and lymphangiogenesis in malignant processes. The aim of this study was to investigate plasma concentrations of VEGF-A, VEGF-B and their soluble VEGFR-1 receptor and their diagnostic utility and potency as compared to CA 15-3 in breast cancer patients and in relation to the control group. The study included 120 breast cancer patients and 60 control patients. Plasma levels of tested parameters were determined with ELISA and CA 15-3 levels were determined with CMIA. Concentrations of all tested parameters in breast cancer patients showed statistically significant difference when compared to the control groups (benign breast tumor patients and/or healthy women). VEGF-B showed the highest values of sensitivity (Sn) and predictive value of a negative test result (NPV) in total BC group (90% and 66.7%, respectively) and, more importantly, in stages I–II of BC (SE: 86.8%; 92.7%, NPV: 82.8%; 88.9%, respectively). Among all parameters tested, VEGF-A showed the highest specificity (Sf) (76.7%) and predictive value of a positive test result (PPV) (84.8%), yet they were lower than for CA 15-3. VEGF-A was also the best parameter that had statistically significant Area Under Curve (AUC) in stages I (0.678) and II (0.768). In the whole group of BC patients all parameters tested showed statistically significant AUC, but the maximum range was obtained for the combination of VEGF-A and CA 15-3 (0.817). The combined analysis of the studied parameters and CA 15-3 resulted in an increase in sensitivity and AUC values, which provides hope for developing a new panel of biomarkers that may be used in BC diagnosis in the future.
机译:VEGF家族成员是促进恶性过程中血管生成和淋巴管生成的重要因素。这项研究的目的是研究乳腺癌患者以及与对照组相比,VEGF-A,VEGF-B及其可溶性VEGFR-1受体的血浆浓度及其与CA 15-3相比的诊断效用和效价。该研究包括120名乳腺癌患者和60名对照患者。用ELISA测定被测参数的血浆水平,用CMIA测定CA 15-3的水平。与对照组(良性乳腺肿瘤患者和/或健康女性)相比,乳腺癌患者中所有测试参数的浓度均显示出统计学上的显着差异。 VEGF-B在总BC组(分别为90%和66.7%)中表现出最高的敏感性(Sn)值和阴性测试结果(NPV)的预测值,更重要的是,在BC的I–II期(SE :86.8%; 92.7%; NPV:82.8%; 88.9%)。在所有测试参数中,VEGF-A表现出最高的特异性(Sf)(76.7%)和阳性检测结果(PPV)的预测值(84.8%),但低于CA 15-3。 VEGF-A也是在阶段I(0.678)和阶段II(0.768)中具有统计学显着性的曲线下面积(AUC)的最佳参数。在整个BC患者组中,所有测试参数均显示统计学上显着的AUC,但获得了VEGF-A和CA 15-3组合的最大范围(0.817)。对所研究参数和CA 15-3的组合分析导致灵敏度和AUC值增加,这为开发新的生物标志物组提供了希望,这些标志物将来可用于BC诊断。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号